SONN beat EPS expectations by 96.71%
May 27, 2024, 4:34 PM
-53.42%
What does SONN do
Sonnet BioTherapeutics Holdings, Inc., a biotech firm based in Princeton, New Jersey, specializes in oncology with a focus on enhancing drug delivery and efficacy using its FHAB technology. The company, which went public in 2005, is advancing clinical trials in solid tumors and neuropathies with key assets like SON-1010 and SON-080.
Sonnet BioTherapeutics Holdings Inc (SONN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Sonnet BioTherapeutics Holdings Inc's actual EPS was $0.07, beating the estimate of $0.14 per share, resulting in a 96.71% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.